CN110475558A - 糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用 - Google Patents

糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用 Download PDF

Info

Publication number
CN110475558A
CN110475558A CN201880015928.3A CN201880015928A CN110475558A CN 110475558 A CN110475558 A CN 110475558A CN 201880015928 A CN201880015928 A CN 201880015928A CN 110475558 A CN110475558 A CN 110475558A
Authority
CN
China
Prior art keywords
patient
glucocorticoid receptor
catecholamine
gra
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880015928.3A
Other languages
English (en)
Chinese (zh)
Inventor
A·G·莫来提斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CN110475558A publication Critical patent/CN110475558A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
CN201880015928.3A 2017-03-09 2018-03-08 糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用 Pending CN110475558A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469296P 2017-03-09 2017-03-09
US62/469,296 2017-03-09
PCT/US2018/021592 WO2018165460A1 (en) 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Publications (1)

Publication Number Publication Date
CN110475558A true CN110475558A (zh) 2019-11-19

Family

ID=63446773

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880015928.3A Pending CN110475558A (zh) 2017-03-09 2018-03-08 糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用

Country Status (8)

Country Link
US (1) US11045482B2 (https=)
EP (1) EP3592358A4 (https=)
JP (3) JP7564620B2 (https=)
CN (1) CN110475558A (https=)
AU (1) AU2018230429B2 (https=)
CA (1) CA3053806A1 (https=)
MX (1) MX2019010732A (https=)
WO (1) WO2018165460A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105746TA (en) 2018-12-20 2021-07-29 Corcept Therapeutics Inc Methods for imaging and treatment of somatostatin-receptor positive tumors
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201141522A (en) * 2010-02-05 2011-12-01 Phosphagenics Ltd Carrier composition
US20160310507A1 (en) * 2015-04-21 2016-10-27 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
CA2325169A1 (en) 1999-12-03 2001-06-03 Ndsu Research Foundation Somatostatins and method
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
DE60232956D1 (de) 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
US7189856B2 (en) 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
CA2558899C (en) 2004-03-09 2013-02-05 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US20100178663A1 (en) * 2007-05-15 2010-07-15 Waters Technologies Corporation Apparatus And Methods For The Detection Of Plasma Metanephrines
US20100261693A1 (en) 2007-10-17 2010-10-14 Ulmann Andre Method for treating cushing's syndrome
ES2351569B8 (es) 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
JP5637568B2 (ja) 2009-05-12 2014-12-10 コーセプト セラピューティクス， インコーポレイテッド 固体形態および調製のためのプロセス
MY161170A (en) 2011-03-18 2017-04-14 Corcept Therapeutics Inc Pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3848027T3 (pl) 2013-11-25 2023-07-24 Corcept Therapeutics Incorporated Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego
AU2016226451B2 (en) * 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201141522A (en) * 2010-02-05 2011-12-01 Phosphagenics Ltd Carrier composition
US20160310507A1 (en) * 2015-04-21 2016-10-27 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F W REUTTER ET AL.: ""Importance of detecting rapid changes in blood catechol amine levels in the diagnosis of pheochromocytoma", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *
张丽结等: "胰岛素、地塞米松和米非司酮对PC12细胞合成和分泌儿茶酚胺的影响及机制探究", 《药学进展》 *
郭妮妮等: "米非司酮对胰岛素抵抗大鼠儿茶酚胺含量的影响及可能机制", 《江苏医药》 *

Also Published As

Publication number Publication date
JP2020510011A (ja) 2020-04-02
AU2018230429A1 (en) 2019-09-05
JP2024074854A (ja) 2024-05-31
JP7564620B2 (ja) 2024-10-09
JP2022090003A (ja) 2022-06-16
EP3592358A4 (en) 2020-12-16
AU2018230429B2 (en) 2023-06-15
EP3592358A1 (en) 2020-01-15
WO2018165460A1 (en) 2018-09-13
US20180256604A1 (en) 2018-09-13
US11045482B2 (en) 2021-06-29
CA3053806A1 (en) 2018-09-13
MX2019010732A (es) 2019-11-01

Similar Documents

Publication Publication Date Title
US11073523B2 (en) Method for differentially diagnosing ACTH-dependent Cushing's syndrome
JP6821582B2 (ja) Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
de Bruin et al. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s syndrome
CA3034114C (en) Glucocorticoid receptor modulators to treat pancreatic cancer
JP2024074854A (ja) カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
Mancini et al. Treatment of Cushing disease: overview and recent findings
JP7670462B2 (ja) 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
CN107530339B (zh) 糖皮质激素受体拮抗剂联合糖皮质激素用于治疗肾上腺功能不全
JP2023052618A (ja) 糖質コルチコイド受容体モジュレータおよびｃｙｐ３ａインヒビタの併用投与
Edling et al. An update on the treatment of acromegaly
US20080206194A1 (en) Method for the treatment of breast cancer
Neggers et al. Medical approach to pituitary tumors
van der Pas et al. Recent developments in drug therapy for Cushing’s disease
De First Approval of Elacestrant as a Selective Estrogen Receptor Degrader for the Treatment of Metastatic Breast Cancer
Bonert et al. 10 Acromegaly
HK1255714B (en) Method for differentially diagnosing acth-dependent cushing's syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination